Alex P Michael1, Victoria L Watson2, Daniel Ryan3, Kristin R Delfino4, Simon V Bekker5, Jeffrey W Cozzens2. 1. Division of Neurosurgery, Southern Illinois University School of Medicine, 421 N. 9th Street, Springfield, IL, 62702, USA. amichael@siumed.edu. 2. Division of Neurosurgery, Southern Illinois University School of Medicine, 421 N. 9th Street, Springfield, IL, 62702, USA. 3. Department of Radiology, Southern Illinois University School of Medicine, 421 N. 9th Street, Springfield, IL, 62702, USA. 4. Center for Clinical Research, SIU School of Medicine, 201 E. Madison, P.O. Box 19664, Springfield, IL, 62794-9664, USA. 5. Department of Radiology, Southern Illinois University School of Medicine, 111 Oakwood Road, East Peoria, IL, 61611, USA.
Abstract
PURPOSE: Fluorescence-guided surgery (FGS) with the use of 5-aminolevulinic acid (5-ALA) leads to more extensive resection of high-grade glioma (HGG) and longer overall survival (OS) of patients compared to conventional resection. The purpose of this study is to investigate the effect of 5-ALA dosages on residual tumor volume (RTV) and OS in patients with glioblastoma. METHODS: A retrospective cohort study for patients who participated in a phase I and II dose-escalation clinical trial on 5-ALA for resection of HGG. A total of 25 patients were found to have newly diagnosed glioblastoma on histology and enrolled in our study. Patients receiving low doses of 5-ALA (10-30 mg/kg) (n = 6) were compared to those receiving high doses (40-50 mg/kg) (n = 19). Pre- and post-operative contrast enhanced T1W MRI were evaluated with volumetric analysis. RESULTS: Median RTV was 0.69 cm3 and 0.00 cm3 in the low and high dose groups respectively (p = 0.975). A gross total resection (GTR) was more likely in the high dose group, though this was not statistically significant. No significant difference was found in median OS between the high and low dose groups (p = 0.6787). CONCLUSIONS: High doses of 5-ALA FGS are associated with less RTV and greater probability of GTR. 5-ALA dose was not associated with OS. Further studies with a larger patient cohort are warranted.
PURPOSE: Fluorescence-guided surgery (FGS) with the use of 5-aminolevulinic acid (5-ALA) leads to more extensive resection of high-grade glioma (HGG) and longer overall survival (OS) of patients compared to conventional resection. The purpose of this study is to investigate the effect of 5-ALA dosages on residual tumor volume (RTV) and OS in patients with glioblastoma. METHODS: A retrospective cohort study for patients who participated in a phase I and II dose-escalation clinical trial on 5-ALA for resection of HGG. A total of 25 patients were found to have newly diagnosed glioblastoma on histology and enrolled in our study. Patients receiving low doses of 5-ALA (10-30 mg/kg) (n = 6) were compared to those receiving high doses (40-50 mg/kg) (n = 19). Pre- and post-operative contrast enhanced T1W MRI were evaluated with volumetric analysis. RESULTS: Median RTV was 0.69 cm3 and 0.00 cm3 in the low and high dose groups respectively (p = 0.975). A gross total resection (GTR) was more likely in the high dose group, though this was not statistically significant. No significant difference was found in median OS between the high and low dose groups (p = 0.6787). CONCLUSIONS: High doses of 5-ALAFGS are associated with less RTV and greater probability of GTR. 5-ALA dose was not associated with OS. Further studies with a larger patient cohort are warranted.
Authors: Mylan R Blomquist; Shannon Fortin Ensign; Fulvio D'Angelo; Joanna J Phillips; Michele Ceccarelli; Sen Peng; Rebecca F Halperin; Francesca P Caruso; Luciano Garofano; Sara A Byron; Winnie S Liang; David W Craig; John D Carpten; Michael D Prados; Jeffrey M Trent; Michael E Berens; Antonio Iavarone; Harshil Dhruv; Nhan L Tran Journal: Neurooncol Adv Date: 2020-06-19
Authors: Oluwakanyinsolami Netufo; Kate Connor; Liam P Shiels; Kieron J Sweeney; Dan Wu; Donal F O'Shea; Annette T Byrne; Ian S Miller Journal: Pharmaceuticals (Basel) Date: 2022-04-29
Authors: Jaejoon Lim; YoungJoon Park; Ju Won Ahn; So Jung Hwang; Hyouksang Kwon; Kyoung Su Sung; Kyunggi Cho Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240
Authors: Barbara Kiesel; Lisa I Wadiura; Mario Mischkulnig; Jessica Makolli; Veronika Sperl; Martin Borkovec; Julia Freund; Alexandra Lang; Matthias Millesi; Anna S Berghoff; Julia Furtner; Adelheid Woehrer; Georg Widhalm Journal: Cancers (Basel) Date: 2021-12-04 Impact factor: 6.639